Literature DB >> 4006774

Effect of intravenous flecainide on atrial vulnerability in man.

T Pop, N Treese.   

Abstract

Sixteen patients were investigated by means of programmed atrial stimulation at 2 different driving rates: 100/min and 120/min. All patients had an increased atrial vulnerability at both driving rates. After the administration of intravenous flecainide (1 mg/kg bodyweight as a bolus, followed by the same amount infused over a period of 20 minutes), the increased vulnerability was abolished in 11 and 9 patients, respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a corresponding significant shortening of its relative refractory period. It is concluded that flecainide may be effective in the treatment of atrial arrhythmias in humans.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006774     DOI: 10.2165/00003495-198500294-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  [Electrocardiology basis of paroxysmal atrial fibrillation (author's transl)].

Authors:  T Pop; D Fleischmann; C Bethge
Journal:  Z Kardiol       Date:  1979-11

2.  Effects of digitalis on atrial vulnerability.

Authors:  T R Engel; A D Gonzalez
Journal:  Am J Cardiol       Date:  1978-10       Impact factor: 2.778

3.  [Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)].

Authors:  L Seipel; R R Abendroth; G Breithardt
Journal:  Z Kardiol       Date:  1981-07

4.  The vulnerability of the right atrium. III. Electrophysiologic correlates of atrial vulnerability.

Authors:  T Pop; D Fleischmann; S Effert
Journal:  Klin Wochenschr       Date:  1979-01-01

5.  Antiarrhythmic effects of flecainide.

Authors:  P Somani
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

6.  Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial.

Authors: 
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

7.  Oral flecainide acetate for the treatment of ventricular arrhythmias.

Authors:  J L Anderson; J R Stewart; B A Perry; D D Van Hamersveld; T A Johnson; G J Conard; S F Chang; D C Kvam; B Pitt
Journal:  N Engl J Med       Date:  1981-08-27       Impact factor: 91.245

8.  Effects of cycle length on atrial vulnerability.

Authors:  C R Wyndham; F Amat-y-Leon; D Wu; P Denes; R Dhingra; R Simpson; K M Rosen
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

9.  Prolonged atrial conduction. A major predisposing factor for the development of atrial flutter.

Authors:  C V Leier; J A Meacham; S F Schaal
Journal:  Circulation       Date:  1978-02       Impact factor: 29.690

10.  The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.

Authors:  D A Deano; D Wu; R K Mautner; R H Sherman; A I Ehsani; K M Rosen
Journal:  Chest       Date:  1977-05       Impact factor: 9.410

View more
  1 in total

Review 1.  Clinical electrophysiologic effects of flecainide acetate.

Authors:  D Mehta; A J Camm; D E Ward
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.